CLDX

Insider Trades

Name	Value	Action	Price	Current Price
Jimenez Freddy A.SVP & GENERAL COUNSEL $121k4.2k shares SellDec 4, 2025 $29.10 --
Wright Richard M.Other: Former Officer $1.2M49.3k shares SellNov 13, 2025 $24.00 --
Jimenez Freddy A.SVP & GENERAL COUNSEL $11k430 shares SellAug 13, 2025 $25.42 --
Jimenez Freddy A.SVP & GENERAL COUNSEL $8.2k341 shares SellAug 13, 2025 $23.95 --
Marucci Anthony SDirector, Officer: PRESIDENT & CEO $308k11.5k shares BuyNov 11, 2024 $26.82 --
Crowley ElizabethSR. VP & CPDO $1.0M30k shares SellJun 14, 2024 $34.87 --

News

globenewswire.comCelldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.comJun 14

globenewswire.comCelldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meetingglobenewswire.comJun 14

globenewswire.comCelldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congressglobenewswire.comJun 10

zacks.comCelldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimateszacks.comMay 7

Trade CLDX

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.

CEO: Anthony S. Marucci
IPO Date: May 15, 1986

Market Data

Open: $33.69
High: $34.11
Low: $32.38
Volume: 1.8M
Avg Volume: 958.2K
52W High: $35.79
52W Low: $19.52

Valuation

Market Cap: $2.2B
Enterprise Value: $2.1B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-214M
Revenue: $1.5M
Net Income: $-259M
Cash: $29M
Debt: $2.3M

Events

EarningsAug 6

EPS est. -1.04